Evexta Bio and Roche Partner to Evaluate Rupitasertib Combination in Advanced Breast Cancer
PARIS, Aug. 4, 2026 Evexta Bio announced a clinical trial collaboration and supply agreement with Roche to evaluate its...
targeted therapy
Advertisement
InnoCare Secures China Breakthrough Therapy Status for Marginal Zone Lymphoma Therapy
BEIJING, Aug. 4, 2026 InnoCare Pharma announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation...
Rocket Pharmaceuticals Reports Positive RP-A501 Safety Update
CRANBURY, N.J., Aug. 3, 2026 Rocket Pharmaceuticals, Inc. announced a positive clinical safety update from the first three patients...
Zai Lab Receives FDA Orphan Drug Designation for Zoci
SHANGHAI & CAMBRIDGE, Mass., Aug. 3, 2026 Zai Lab Limited announced that the U.S. Food and Drug Administration (FDA)...
Firefly Bio Acquisition Strengthens J&J Cancer Portfolio
MONTEREY, Calif., July 29, 2026 Johnson & Johnson has completed its $1 billion acquisition of Firefly Bio, Inc., significantly...
Advertisements
AstraZeneca’s Sone-Ve Delivers Phase III Survival Breakthrough
CAMBRIDGE, UK, July 27, 2026 AstraZeneca has announced positive high-level results from the global Phase III CLARITY-Gastric01 trial, demonstrating...
Elephas Biosciences Expands elive™ Platform to Targeted Therapies
MADISON, Wis. – July 24, 2026 Elephas Biosciences Corporation has unveiled new preclinical data demonstrating that its elive™ functional...
Verastem Oncology Doses First Patient in Phase 2 VS-7375 NSCLC Trial
BOSTON, July 22, 2026 Verastem Oncology has announced that the first patient has been dosed in the TARGET-D 202...
GSK Wins FDA Approval for Jideytro in ROS1+ Lung Cancer
LONDON, United Kingdom, July 23, 2026 GSK plc has announced that the U.S. Food and Drug Administration (FDA) has...
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx
MELBOURNE, Australia, and INDIANAPOLIS, Ind., July 21, 2026 Telix Pharmaceuticals announced that the first patient has been dosed in...
Advertisement
